Develops dietary supplements for microvascular health.
Mar 2026Revenue $1.77M/yrExpenses $2.87M/yr
No trend
Figures by year
When will Bioregenx be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $1.77M and expenses $2.87M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.85M | $3.10M | −$1.24M |
| Dec 2024 | $2.34M | $25.1M | −$22.8M |
| Dec 2023 | $3.41M | $6.82M | −$3.41M |
| Dec 2022 | $42.2K | $120K | −$78.3K |
| Dec 2021 | $199K | $364K | −$165K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.